康莱特联合化疗治疗中晚期肺癌的疗效观察

目的观察康莱特联合化疗治疗中晚期肺癌的临床效果。方法98Fq晚期肺癌患者随机分成观察组与对照组，观察组采取康莱特加化疗，对照组采取单纯化疗。分别测定两组患者治疗前、后外周血T淋巴细胞亚群及NK细胞的活性，并观察两组的临床疗效、生活质量、体重变化和不良反应等情况。结果治疗后观察组和对照组的有效率分别为58．0％和37．5％（P〈0．05）；观察组T淋巴细胞亚群和NK细胞活性明显高于对照组（P〈0．05），免疫功能明显改善；观察组Karnofsky评分上升率（52．0％）高于对照组（31．2％）（P〈0．05）。结论康莱特联合化疗治疗中晚期肺癌的疗效优于单纯化疗，能减轻不良反应，提高患者的生存质量。

Objective The aim of this study is to observe the efficacy of Kanglaite injection combined with chemotherapy in advanced lung cancer. Methods Nighty-eight patients with advanced lung cancer were randomly divided into two groups： ①Kanglaite injection ＋ chemotherapy group （ experiment group, 50cases ） ; ②Simple chemotherapy group （ comparison group, 48 cases ） . The peripheral blood T lymphocyte subsets and natural killer （ NK ） cell activity of patients in both groups were measured before and after treatment. The immune functions, the effect of treatment, quality of life, and adverse reactions were observed. Results After treatment the objective response rate （ CR ＋ PR ） was 58.0% in experiment group, compared to 37.5% in comparison group （ P〈0.05 ） .The blood T cell levels and NK cell activity in experiment group increased than comparison group （ P〈0.05 ） . Quality of life in experiment group was higher than that in comparison group （ P〈0.05 ） . Conclusion The therapeutic effect of Kanglaite injection combined with chemotherapy is better than that of chemotherapy alone.It can reduce the side of chemotherapy and the quality of life.